Key result
Non-cardiac surgery performed at least six months after drug-eluting stent implantation was associated with a 7.7% rate of major adverse cardiac events at 30 days.
Why the study?
What is the risk of cardiac complications following noncardiac surgery in patients with drug-eluting stents implanted at least six months prior?
Population
78 patients who underwent drug-eluting stent placement and subsequently had noncardiac surgery
Design
Cohort
Follow-up
30-day
Authors
Loading...
Risk remains clinically relevant beyond 6 months; leaves open optimal perioperative antiplatelet and timing strategies for trials.
Observational (n=78)
No
What is the risk of cardiac complications following noncardiac surgery in patients with drug-eluting stents implanted at least six months prior?
Patients undergoing non-cardiac surgery at least 6 months after DES implantation still face a notable risk of major adverse cardiac events, including stent thrombosis, even when maintained on dual antiplatelet therapy.
Assali et al. (2009) conducted an observational in Patients with drug-eluting stents undergoing non-cardiac surgery (n=78). Non-cardiac surgery at least six months after drug-eluting stent implantation was evaluated on 30-day rate of major adverse cardiac events (cardiac death and non-fatal myocardial infarction). Non-cardiac surgery performed at least six months after drug-eluting stent implantation was associated with a 7.7% rate of major adverse cardiac events at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: